Coverage
-
July 06, 2016
A Manhattan federal judge on Wednesday ditched a proposed class action alleging that the former CEO of a bankrupt pharmaceutical company had lied about the efficacy of an intended dual painkiller treatment before pulling it from development, saying the cited statements were not misleading.
1 other articles on this case.
View all »